NCT01769417View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Staphylococcus Aureus
Interventions
DRUG

Placebo

Placebo

DRUG

MEDI4893

Human immunoglobulin G1 kappa monoclonal antibody

Trial Locations (1)

Unknown

Research Site, Miami

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT01769417 - A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter